Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054444 | 0.93 | PDE4B (0.56) | PDE4BKDM4CTBXAS1SMN1; SMN2TP53 | |
| SCHEMBL3022923 | 0.92 | PDE4B (0.52) | PDE4BKDM4CALDH1A1RAB9ATBXAS1 | |
| SCHEMBL4052791 | 0.89 | PDE4B (0.41) | PDE4BKDM4CALDH1A1RAB9ATBXAS1 | |
| SCHEMBL3032862 | 0.87 | PDE4B (0.65) | PDE4BKDM4CTBXAS1SMN1; SMN2TP53 | |
| SCHEMBL4050885 | 0.87 | PDE4B (0.43) | PDE4BKDM4CTBXAS1SMN1; SMN2TP53 | |
| SCHEMBL1652356 | 0.86 | PDE4B (0.63) | PDE4BTBXAS1SMN1; SMN2TP53 | |
| SCHEMBL3036647 | 0.86 | PDE4B (0.54) | PDE4BKDM4CTBXAS1SMN1; SMN2TP53 | |
| SCHEMBL3039906 | 0.84 | PDE4B (0.51) | PDE4BKDM4CALDH1A1TBXAS1GAA | |
| SCHEMBL4060223 | 0.84 | PDE4B (0.55) | PDE4BALDH1A1RAB9ATBXAS1SMN1; SMN2 | |
| SCHEMBL4052341 | 0.84 | PDE4B (0.38) | PDE4BKDM4CALDH1A1RAB9ATBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029996-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| EP-1781621-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Laboratorios Almirall, S.A. (ES) | 2007-05-09 | — | — | EP | disclosed |
| WO-2005123693-A1 | PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | LABORATORIOS ALMIRALL, S.A. (ES) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029996-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE4B | PDE4B 3/4885KDM4C 289/4885ALDH1A1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.